^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cabazitaxel

    i
    Other names: XRP6258, XRP-6258, TXD-258, taxoid-116258, RPR 116258, RPR 116258A, TXD 258
    Company:
    Generic mfg.
    Drug class:
    Microtubule inhibitor
    Related drugs:
    3d
    DAROTAXEL (2024-516939-28-00`2022-003792-41)
    P1/2, N=245, Recruiting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Nubeqa (darolutamide) • cabazitaxel
    7d
    Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (clinicaltrials.gov)
    P1/2, N=30, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)
    |
    TP53 mutation • PTEN mutation • LDH elevation
    |
    carboplatin • cabazitaxel • Hepacid (pegargiminase)
    8d
    Chemotherapy-Forward Management of Advanced Prostate Cancer: Taxane Timing, Sequencing and the Real-World Place of Immunotherapy. (PubMed, Cancers (Basel))
    In mCRPC, docetaxel remains foundational, while cabazitaxel is preferred over ARPI switching after prior docetaxel and one ARPI, supporting mechanism-based sequencing. Immunotherapy has a limited but important niche: sipuleucel-T may benefit selected patients with low symptom burden, whereas immune checkpoint inhibitors are best reserved for biomarker-defined subsets such as microsatellite instability-high or mismatch repair-deficient tumors; tumor mutational burden should be interpreted cautiously in prostate cancer. Ongoing trials and emerging antigen-directed platforms will clarify whether chemotherapy can act as an immune-enabling partner in defined settings.
    Review • Journal • Real-world evidence • Tumor mutational burden • MSi-H Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    docetaxel • cabazitaxel • Provenge (sipuleucel-T)
    10d
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    10d
    c15-148: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    Xtandi (enzalutamide) • cabazitaxel
    14d
    FASN: Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Wake Forest University Health Sciences | Trial completion date: Apr 2028 --> Apr 2030 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    docetaxel • cabazitaxel • omeprazole
    16d
    Modulation of the intestinal microbiome and reversal of the immunosuppressive microenvironment by nanoparticles for chemoimmunotherapy in prostate cancer. (PubMed, J Adv Res)
    CBZ/FA-CA-OCD NPs improve PCa chemoimmunotherapy by regulating gut microbiota, reversing immunosuppression, and enhancing T-cell infiltration. This nanomedicine-based strategy provides a promising approach to boost PCa treatment outcomes.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    cabazitaxel
    17d
    20230239: Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-nave Metastatic Castration-resistant Prostate Cancer (2025-520555-89-00)
    P2/3, N=295, Recruiting, Amgen Inc.
    New P2/3 trial
    |
    docetaxel • abiraterone acetate • cabazitaxel • Sylvant (siltuximab) • xaluritamig (AMG 509)
    17d
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    22d
    A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=277, Recruiting, Janssen Research & Development, LLC | N=185 --> 277
    Enrollment change
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • apalutamide • cetrelimab (JNJ-63723283) • pasritamig (JNJ-8343)
    29d
    AcTFirst: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (clinicaltrials.gov)
    P3, N=940, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Feb 2028 --> Sep 2028
    Trial primary completion date
    |
    HRD (Homologous Recombination Deficiency)
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • 225Ac-vipivotide tetraxetan (AAA817)
    29d
    Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer. (PubMed, Clin Cancer Res)
    177Lu-PSMA-617 strongly promotes CH, supporting integration of longitudinal monitoring for long-term hematologic sequelae as radioligand therapy is implemented earlier in prostate cancer care.
    Journal
    |
    PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D)
    |
    docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)